Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Program Description

As the most prevalent breast cancer subtype, accounting for approximately 70% of all cases, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC) remains a critical challenge, with a 5-year relative survival rate of approximately 36.5% for distant disease. A need for therapies to overcome primary and acquired endocrine resistance and prevent tumor relapse has contributed to the rapidly evolving treatment landscape. However, the introduction of novel therapies presents significant complexities for formulary development and resource utilization. This session provides managed care professionals and oncology pharmacists with the latest therapeutic strategies in HR+/HER2– MBC and their implications for patient care and formulary management. Expert faculty will discuss the critical role of biomarker testing in guiding individualized treatment sequencing across multiple lines of therapy. The pharmacology, clinical evidence, and appropriate use of novel agents, including CDK4/6 inhibitors, oral selective estrogen receptor degraders (SERDs), PIK3CA/AKT1/PTEN inhibitors, PARP inhibitors, and antibody-drug conjugates (ADCs) will be explored alongside strategies to navigate treatment selection among approved agents, optimize resource utilization, ensure appropriate genomic testing, and improve patient access to novel therapies within the managed care environment.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Interpret current guideline recommendations and biomarker testing strategies to support individualized treatment planning in HR-positive/HER2-negative (HR+/HER2–) metastatic breast cancer.
• Analyze efficacy and safety data from recent clinical trials assessing novel agents and combination regimens in the first line setting for HR+/HER2– metastatic breast cancer.
• Explain the role of novel targeted therapies in the treatment continuum beyond progression on CDK4/6 inhibitors for HR+/HER2– disease.
• Investigate the impact of evolving clinical evidence on formulary decision-making, value-based pathway development, and care optimization strategies for HR+/HER2– metastatic breast cancer.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-363-H01-P. The activity is available for CE credit through November 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Laura R. Bobolts, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose: Consultant: Pfizer

Rose DiMarco, PharmD, BCPS, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Consultant: CE Synergy, Lilly, IO Biotech, Jazz; Speakers Bureau: Lilly 

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Amy L. Morris, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms